Cefpodoxime: Difference between revisions
Gerald Chi (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cefpodoxime}} | {{Cefpodoxime}} | ||
{{CMG}};{{AE}}{{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==Overview== | ==Overview== | ||
Cefpodoxime (marketed as the [[prodrug]] cefpodoxime proxetil by [[Pharmacia & Upjohn]] under the trade name Vantin®) is an oral third generation [[cephalosporin]] [[antibiotic]]. It is active against most [[Gram positive]] and [[Gram negative]] [[bacteria]]. Notable exceptions include ''[[Pseudomonas aeruginosa]]'', ''[[Enterococcus]]'', and ''[[Bacteroides|Bacteroides fragilis]]''. It is commonly used to treat acute [[otitis media]], [[pharyngitis]], and [[sinusitis]]. It also finds use as oral continuation therapy when [[intravenous]] cephalosporins (such as [[ceftriaxone]]) are no longer necessary for continued treatment. [[Pfizer]], the parent company of [[Pharmacia & Upjohn]], markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®. | |||
==Category== | ==Category== | ||
| Line 14: | Line 15: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
[[Cefpodoxime description|Description]] | |||
| [[Cefpodoxime clinical pharmacology|Clinical Pharmacology]] | |||
| [[Cefpodoxime microbiology|Microbiology]] | |||
| [[Cefpodoxime indications and usage|Indications and Usage]] | |||
| [[Cefpodoxime contraindications|Contraindications]] | |||
| [[Cefpodoxime warnings|Warnings]] | |||
| [[Cefpodoxime precautions|Precautions]] | |||
| [[Cefpodoxime adverse reactions|Adverse Reactions]] | |||
| [[Cefpodoxime overdosage|Overdosage]] | |||
| [[Cefpodoxime clinical studies|Clinical Studies]] | |||
| [[Cefpodoxime dosage and administration|Dosage and Administration]] | |||
| [[Cefpodoxime how supplied|How Supplied]] | |||
| [[Cefpodoxime labels and packages|Labels and Packages]] | |||
==References== | ==References== | ||
Revision as of 13:33, 15 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Cefpodoxime (marketed as the prodrug cefpodoxime proxetil by Pharmacia & Upjohn under the trade name Vantin®) is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. Pfizer, the parent company of Pharmacia & Upjohn, markets Cefpodoxime proxetil under the trade name Simplicef® for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Outside the US, Cefpodoxime proxetil is marketed as Banan®.
Category
Cephalosporins, third generation.
US Brand Names
VANTIN®
FDA Package Insert
Description
| Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050674s015,050675s018lbl.pdf